Skip to content
Catalyst

PapersPMID:19593179

A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.

Journal of clinical psychopharmacology2009The record ↗

findings
4
compound
1
endpoints
4
no difference found
3
PMID:19593179
  1. Finding, moderate evidencelowersHamilton Anxiety Rating Scale (HAM-A) total score
  2. Finding, moderate evidenceno difference foundBody mass
  3. Finding, moderate evidenceno difference foundSystolic blood pressure
  4. Finding, moderate evidenceno difference foundDiastolic blood pressure
Study, every finding
RCT · 8 weeks
Dose studied, every finding
220 mg capsules, 1 daily in week 1, 2 daily in week 2, titrated by HAM-A response to up to 5 daily (1100 mg/day) in weeks 5-8
Population, every finding
adult outpatients with mild to moderate generalized anxiety disorder (DSM-IV, baseline HAM-A >= 9)
  • “QLS analysis found a significantly greater reduction over time in the mean total HAM-A score for chamomile versus placebo (60 β̂3 = −3.17, 95% CI, −6.29 to −0.45) (p=0.047).”
    Interests
    An author is affiliated with a producer

What did not

Study record

Design
randomised controlled trial
Species
human
Population
Outpatients with mild to moderate generalized anxiety disorder (DSM IV), minimum baseline HAM-A score ≥ 9
Participants
57
Comparator
placebo
Duration
56 days
Endpoints measured
19